Literature DB >> 15695554

Borrelia burgdorferi, an extracellular pathogen, circumvents osteopontin in inducing an inflammatory cytokine response.

Kathleen Craig-Mylius1, Georg F Weber, Jenifer Coburn, Lisa Glickstein.   

Abstract

A classic proinflammatory T helper cell type 1 (TH1) response directed against intracellular pathogens includes the cytokine osteopontin, which acts predominantly on macrophages, where it induces the secretion of interleukin (IL)-12 and suppresses the secretion of IL-10. As cell-mediated immune responses play an important role in the resistance to Lyme arthritis, a manifestation of infection by the extracellular pathogen Borrelia burgdorferi, we tested the hypothesis that osteopontin may be required to induce T(H)1 responses and inflammation. The role of osteopontin was tested in vivo and using ex vivo macrophages in B6129F3 mice susceptible to experimental Lyme arthritis. Mice of this genetic background and those fully backcrossed to C57BL/6, which lacked osteopontin expression (spp1-/-), were as susceptible to B. burgdorferi-induced arthritis as littermate controls. Furthermore, equal numbers of spirochetes, as measured by quantitative polymerase chain reaction of the B. burgdorferi gene recA in spp1-/- and B6129F3 wild-type littermates, suggested that susceptibility to infection was not dependent on this cytokine. Neither of the B6129F3 parental mouse strains lacked the ability to secrete osteopontin. spp1-/- mice and controls had immunoglobulin G2 titers, suggestive of a TH1 response. B. burgdorferi was able to directly stimulate the secretion of the proinflammatory cytokines IL-12 and tumor necrosis factor alpha from wild-type and spp1-/- macrophages alike. These results indicate that the usually critical role of osteopontin in the induction of cellular immune responses to intracellular pathogens was circumvented by the ability of the extracellular pathogen B. burgdorferi to induce macrophages directly to produce proinflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695554     DOI: 10.1189/jlb.0604356

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis.

Authors:  Xin Li; Gail A McHugh; Nitin Damle; Vijay K Sikand; Lisa Glickstein; Allen C Steere
Journal:  Arthritis Rheum       Date:  2011-08

2.  Effect of Borrelia burgdorferi OspC at the site of inoculation in mouse skin.

Authors:  Styliani Antonara; Laura Ristow; James McCarthy; Jenifer Coburn
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

3.  Borrelia burgdorferi stimulation of chemokine secretion by cells of monocyte lineage in patients with Lyme arthritis.

Authors:  Junghee J Shin; Klemen Strle; Lisa J Glickstein; Andrew D Luster; Allen C Steere
Journal:  Arthritis Res Ther       Date:  2010-09-09       Impact factor: 5.156

4.  Coxiella burnetii Nine Mile II proteins modulate gene expression of monocytic host cells during infection.

Authors:  Saugata Mahapatra; Patricia Ayoubi; Edward I Shaw
Journal:  BMC Microbiol       Date:  2010-09-20       Impact factor: 3.605

5.  Osteopontin impairs host defense during established gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis).

Authors:  Gerritje J W van der Windt; W Joost Wiersinga; Catharina W Wieland; Ivo C S I Tjia; Nicholas P Day; Sharon J Peacock; Sandrine Florquin; Tom van der Poll
Journal:  PLoS Negl Trop Dis       Date:  2010-08-31

Review 6.  Regulation of T-helper-cell lineage development by osteopontin: the inside story.

Authors:  Harvey Cantor; Mari L Shinohara
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

7.  Osteopontin is not crucial to protective immunity during murine tuberculosis.

Authors:  Gerritje J W van der Windt; Catharina W Wieland; Willem J Wiersinga; Sandrine Florquin; Tom van der Poll
Journal:  Immunology       Date:  2009-02-17       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.